Verrica製藥 VRCA 深 滬
等待開盤 05-20 09:30:00 美东时间
5.59
-0.280
-4.77%
華盛通- 最 高5.99
- 今 開5.87
- 成交量 5.03万股
- 最 低 5.56
- 昨 收 5.87
- 總市值 9602.94万
- 52周最高 9.8212
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 3.28
- 委 比 57.69%
- 總股本 1717.88万
- 歷史最高 232.90
- 量 比 0.50
- 振 幅 7.33%
- 歷史最低 3.816
- 每 手 1
- 風險率 1.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call
On Tuesday, Verrica Pharmaceuticals (NASDAQ:VRCA) discussed first-quarter finan...
05-13 17:16
Verrica Pharmaceuticals Q1 Adj. EPS $(0.41) Misses $(0.38) Estimate, Sales $5.023M Beat $4.520M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 53.41 percent increase over losses of $(0.88) per
05-13 04:01
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
Verrica Pharma To Present Phase 2 Clinical Data Highlighting Potential Abscopal Effects Of Oncolytic Peptide, VP-315, In Treatment Of Basal Cell Carcinoma At 2026 SID Annual Meeting
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica")
05-06 04:46
Verrica Pharmaceuticals Q4 Adj. EPS $(0.51) Beats $(0.79) Estimate, Sales $5.092M Beat $4.525M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.79) by 35.77 percent. This is a 71.67 percent increase over losses of $(1.80) per
03-11 20:01
Earnings Scheduled For March 11, 2026
Companies Reporting Before The Bell • Sprinklr (NYSE:CXM) is estimated to repor...
03-11 19:11
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
Verrica Pharmaceuticals Inc. will host a conference call and live webcast on March 11, 2026, at 8:30 a.m. ET to discuss its fourth-quarter and full-year 2025 financial results and provide a corporate update. Participants can join by dialing 1-800-343-4136 (US) or 1-203-518-9843 (international) with conference ID: VERRICA, or via webcast on the investor relations section of www.verrica.com. The webcast will be archived for 90 days. Verrica is a de...
03-05 13:00
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Verrica Pharmaceuticals' CEO, Jayson Rieger, PhD, MBA, will present at the TD Cowen 46th Annual Healthcare Conference in Boston on March 2, 2026, at 10:30am ET. The event will be available via live webcast accessible through the provided links or the Investors section of Verrica's website. Verrica develops medications for skin diseases, including YCANTH® (VP-102) for molluscum contagiosum and common warts, and is collaborating with Lytix Biopharm...
02-23 13:00
Verrica Pharma Announces Launch Of YCANTH In Japan By Its Partner, Torii Pharma, For Treatment Of Molluscum Contagiosum
Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH®
02-09 21:12
